Heron Therapeutics (HRTX) Misses Q2 EPS by 2c

Heron Therapeutics (NASDAQ: HRTX) reported Q2 EPS of ($0.03), $0.02 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $37.67 million versus the consensus estimate of $42.13 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Ladybug Resource Group updates M&A program, holds early financing talks
• Iran's Pezeshkian says country will not surrender to U.S.
• Allstate (ALL) call put ratio 2.8 calls to 1 put with a focus on January 180 and 230 calls